Lifecycle management is the practice of governing a medical device across its entire life, from concept and design through manufacturing, market release, post-market surveillance, change control, and obsolescence. It connects engineering, quality, and regulatory activities under one controlled process so the device stays safe, effective, and compliant throughout its life cycle.

---

What is Lifecycle Management?

Lifecycle management, often called product lifecycle management (PLM), treats a device as a single entity to be controlled from the first design input to the last unit retired from service. In medical devices, this view is formalized. Regulators expect manufacturers to plan, document, and maintain a device across every phase rather than handing it off function by function.

The FDA describes this as the Total Product Life Cycle (TPLC), linking premarket design with postmarket performance. The same idea runs through ISO 13485:2016 and EU MDR 2017/745, where design controls, risk management, and post-market surveillance form one continuous loop. PLM is both a discipline and, in many companies, a software system that holds the device record, change history, and traceability data in one place.

---

Why lifecycle management matters in medical device development

A device does not stop being a regulatory obligation once it ships. Field use generates complaints, adverse events, and design insights that feed back into the field. Weak lifecycle management is a common root cause of audit findings: missing traceability between requirements and verification, change records that skip risk re-assessment, or post-market data that never reaches the design team.

The stakes are concrete. A poorly governed change can invalidate a verification result or trigger a new conformity assessment. Under EU MDR, manufacturers must keep technical documentation current and run active post-market surveillance through Periodic Safety Update Reports (PSUR) and Post-Market Clinical Follow-up (PMCF). In the U.S., the FDA’s Quality Management System Regulation (QMSR), effective February 2026, ties these obligations to ISO 13485:2016 and expects risk-based decisions across the whole system. Gaps cost time, money, and sometimes market access.

---

How lifecycle management works

Lifecycle management runs as a controlled loop, not a straight line. The core phases are:

• Concept and design: capture user needs and design inputs, then apply design controls per ISO 13485 Clause 7.3 and the FDA QMSR.
• Risk management: build and maintain a risk file under ISO 14971:2019, which is explicitly a life-cycle standard updated as new information arrives.
• Verification and validation: prove design outputs meet inputs, with traceability held in the device record.
• Design transfer and manufacturing: move the design to production with validated processes (IQ, OQ, PQ) and disciplined change control.
• Market release and traceability: assign Unique Device Identification (UDI) and register data in systems such as EUDAMED for the EU market.
• Post-market surveillance: collect complaints and field data, then feed signals back into risk and design.
• Sustaining and obsolescence: manage component end-of-life, design changes, and eventual product retirement.

Software-driven devices add IEC 62304, which defines life cycle processes for medical device software from planning through maintenance. Across all phases, change control is the connective tissue. Every modification is assessed for impact on safety, performance, and regulatory status before it is released.

---

Common challenges and best practices

The most frequent failure is treating phases as separate projects. Design hands off to manufacturing, manufacturing hands off to quality, and the thread breaks. When a complaint arrives two years later, no one can trace it back to the design decision that caused it.

Good practice keeps one source of truth. A controlled device record, often a PLM system, links requirements, risk controls, verification evidence, and change history. Teams that plan obsolescence early avoid a scramble when a critical component goes end-of-life. They also scope changes carefully, because a small part substitution can still require revalidation or notified body review, so impact analysis comes first. Mature teams treat post-market data as a design input, closing the loop instead of filing reports and moving on.

---

How SJML helps with Lifecycle Management

SJML supports devices across their full life cycle as an end-to-end CDMO. Its product lifecycle services include sustaining and sustenance engineering, Value Analysis and Value Engineering (VAVE), and obsolescence management to keep aging designs in production. Teams handle RMA and replacement management, sustainability re-engineering, and structured change governance that limits revalidation burden. On the compliance side, SJML offers regulatory sustenance, post-market surveillance planning, and QMS support aligned to ISO 13485 and ISO 14971, helping reduce total cost of ownership while keeping technical documentation current.

Talk to SJML’s engineering team →

---

Frequently asked questions

---

Related terms

• Design Controls
• Risk Management (ISO 14971)
• Post-Market Surveillance
• Change Control
• Obsolescence Management